Novo Nordisk (NVO) reported early Monday that a pill version of its Ozempic failed to slow the progression of Alzheimer’s in two big studies. Novo Nordisk stock dived. Weight-loss drug rival Eli Lilly (LLY) edged lower in premarket trade, along with Amgen (AMGN). Biogen (BIIB), which has Alzheimer’s drugs on the market, rose solidly. Novo Nordisk said that its Evoke and Evoke+…
